Follow-up after infants younger than 2 months of age with urinary tract infection in Southern Israel: epidemiologic, microbiologic and disease recurrence characteristics

Gurevich, Evgenia; Tchernin, Dov; Schreyber, Ruth; Müller, R.; Leibovitz, Eugene

doi:10.1016/j.bjid.2015.09.003

Cited by 10 publications

(8 citation statements)

References 16 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…E. coli outbreak with 13%, was reported the most common urinary germ and in the next ranks were Klebsiella (13%) and Entero bacter (06%) that were similar to most other studies [15][16][17] . 32% of children had abnormal ultrasound.…”

Section: Discussionsupporting

confidence: 85%

Untitled

2017

IJPSR

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 85%

Untitled

2017

IJPSR

View full text Add to dashboard Cite

“…Escherichia coli is the main etiological agent responsible for 70–90% of all UTIs (Gurevich et al, 2016 ; Terpstra and Geerlings, 2016 ). The treatment of patients with UTIs has become increasingly difficult because of the rapid spread of antibiotic resistance (Can et al, 2015 ).…”

Section: Introductionmentioning

confidence: 99%

Comprehensive Molecular Characterization of Escherichia coli Isolates from Urine Samples of Hospitalized Patients in Rio de Janeiro, Brazil

et al. 2018

View full text Add to dashboard Cite

Urinary tract infections (UTIs) are often caused by Escherichia coli. Their increasing resistance to broad-spectrum antibiotics challenges the treatment of UTIs. Whereas, E. coli ST131 is often multidrug resistant (MDR), ST69 remains susceptible to antibiotics such as cephalosporins. Both STs are commonly linked to community and nosocomial infections. E. coli phylogenetic groups B2 and D are associated with virulence and resistance profiles making them more pathogenic. Little is known about the population structure of E. coli isolates obtained from urine samples of hospitalized patients in Brazil. Therefore, we characterized E. coli isolated from urine samples of patients hospitalized at the university and three private hospitals in Rio de Janeiro, using whole genome sequencing. A high prevalence of E. coli ST131 and ST69 was found, but other lineages, namely ST73, ST648, ST405, and ST10 were also detected. Interestingly, isolates could be divided into two groups based on their antibiotic susceptibility. Isolates belonging to ST131, ST648, and ST405 showed a high resistance rate to all antibiotic classes tested, whereas isolates belonging to ST10, ST73, ST69 were in general susceptible to the antibiotics tested. Additionally, most ST69 isolates, normally resistant to aminoglycosides, were susceptible to this antibiotic in our population. The majority of ST131 isolates were ESBL-producing and belonged to serotype O25:H4 and the H30-R subclone. Previous studies showed that this subclone is often associated with more complicated UTIs, most likely due to their high resistance rate to different antibiotic classes. Sequenced isolates could be classified into five phylogenetic groups of which B2, D, and F showed higher resistance rates than groups A and B1. No significant difference for the predicted virulence genes scores was found for isolates belonging to ST131, ST648, ST405, and ST69. In contrast, the phylogenetic groups B2, D and F showed a higher predictive virulence score compared to phylogenetic groups A and B1. In conclusion, despite the diversity of E. coli isolates causing UTIs, clonal groups O25:H4-B2-ST131 H30-R, O1:H6-B2-ST648, and O102:H6-D-ST405 were the most prevalent. The emergence of highly virulent and MDR E. coli in Brazil is of high concern and requires more attention from the health authorities.

show abstract

“…Cefuroxime is available for oral, intravenous, and intramuscular administration; it is rapidly absorbed when given by mouth, the gastrointestinal absorption-rate of the prodrug cefuroxime axetil is 70%, and after hydrolysis it releases cefuroxime [1,3]. Cefuroxime and cefuroxime axetil are efficacy and safe in infants and children [5][6][7][8][9][10] and adverse-effects do not occur even when high doses are given [15]. Parenteral dosing-regimens consist of 25 mg/kg, twice-daily, thrice-daily or 4-times-daily and dose intervals decrease with infant maturation [1].…”

Section: Discussionmentioning

confidence: 99%

“…In literature there is only one study on adverse-effects caused by cefuroxime in children and it was reported by Gold and Rodriguez [15], they stated that cefuroxime is free from adverse-effects.…”

Section: Cefuroxime Adverse-effects In Childrenmentioning

confidence: 99%

Clinical pharmacology of cefuroxime and cefuroxime axetil in infants and children

Pacifici¹

2020

Clin Med Invest

View full text Add to dashboard Cite

Cefuroxime is a second-generation cephalosporin β-lactamase resistant active against gram-negative and gram-positive organisms and the prodrug cefuroxime axetil is the drug of choice for treatment of Lyme disease. Cefuroxime inhibits bacterial cell wall synthesis, is bactericidal, and is one of the few cephalosporins available for oral, intravenous, and intramuscular administration. Cefuroxime is rapidly absorbed when given by mouth, and its blood concentrations remarkably vary among subjects, but the drug has not adverse-effects even when is given at high doses. The gastrointestinal absorption-rate of cefuroxime axetil is 70%, and after hydrolysis it relays cefuroxime. Parenteral dosing-regimens consist of 25 mg/kg in infants and dosing intervals decrease with increasing postnatal age. Cefuroxime oral dosingregimens are: 10, 20 mg/kg and 250 mg twice-daily in children aged up to one year, 2 to 11 and 12 to 17 years, respectively. Elimination half-live are: 6 hours in the first week of life and 1.8 hours in children aged up to 6 years. Cefuroxime is efficacy and safe for prophylaxis and treatment of respiratory-tract and acute urinary-tract infections, pneumoniae, acute otitis media, and sinusitis in children. Prophylaxis for surgical procedures requires 50 mg/kg before procedure and then 30 mg/kg for up 3 days after intervention. Cefuroxime concentration in cerebrospinal fluid is about 10% of that in plasma and the drug successfully treated meningitis caused by β-haemolytic streptococci, Streptococcus pneumoniae, and Neisseria meningitides, but when Salmonella species are the infective pathogens additional 5 mg dose is given intraventricularly. Some bacteria may become resistant to cefuroxime and antibiotic consumption is associated with increased bacterial-resistance. The aim of this study is to review the published data on cefuroxime and cefuroxime axetil dosing, efficacy, safety, and cefuroxime effects, prophylaxis, treatment, optimization, meningitis, pharmacokinetics and bacterial-resistance.

show abstract

Follow-up after infants younger than 2 months of age with urinary tract infection in Southern Israel: epidemiologic, microbiologic and disease recurrence characteristics

Cited by 10 publications

References 16 publications

Untitled

Untitled

Comprehensive Molecular Characterization of Escherichia coli Isolates from Urine Samples of Hospitalized Patients in Rio de Janeiro, Brazil

Clinical pharmacology of cefuroxime and cefuroxime axetil in infants and children

Contact Info

Product

Resources

About